Café

© 2026 Longbridge｜Terms of Service Privacy Policy

ACTU

ACTU

1.0706.96%( -0.080 )

LongbridgeAI

Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.

benzinga_article

Jun 9, 2026 at 07:52 PM

Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.

Source: benzinga_article The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Actuate Therapeutics

ACTU.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--